

Ref no: 028220519
 From: Public
 Date: 22/05/19
 Subject: intra-vitreous injections/implants

REQUEST & RESPONSE

Dear Sir

Within your trust how many intra-vitreous injections/implants have been used in the latest 4 months, if possible between January and April 2019

If your trust is able to identify injections/implants by eye conditions please split by the drug used [ranibizumab, bevacizumab, aflibercept, Fluocinolone and Dexamethasone].

	<i>Lucentis (ranibizumab) Injections</i>	<i>Avastin (bevacizumab) Injections</i>	<i>Eylea (aflibercept) Injections</i>	<i>Iluvien (Fluocinolone) Impants</i>	<i>Ozudex (Dexamethasone) Implants</i>
Total					
<i>Wet Age Related Macular Degeneration (wAMD)</i>	325	0	205	0	0
<i>Diabetic Macular Oedema (DMO)</i>	72	0	31	0	6
<i>Retinal Vein Occlusion - Central or Branch (CRVO or BRVO)</i>	111	0	25	0	*
<i>Other eg mCNV</i>	0	0	0	0	0

*We are unable to provide the information you require as to release this data could lead to the identification of the person(s) involved due to the low numbers involved, and would breach the Trusts obligations under the Data Protection Act 1998. Accordingly, this aspect of your request is exempt from disclosure under the terms of Section 40(2) of the Act.